ASUR vs NVDA

ASUR exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess bankruptcy risk. Despite strong revenue growth of 23.7% and a bullish analyst recommendation (strong_buy), the company is unprofitable with negative profit and operating margins, weak cash conversion, and deteriorating earnings quality. While forward valuation metrics appear reasonable at a Forward P/E of 10.14, the stock trades below its 52-week high and has underperformed peers, offset by improving recent EPS trends and insider sentiment of 60/100. The absence of key financial data (e.g., cash, debt, EV) limits conviction, warranting caution despite growth signals.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.